

## For Health Professionals Who Care For Cancer Patients

### Inside This Issue:

- **Editor's Choice – New Programs:** Osimertinib for Advanced EGFR T790M Mutation-Positive NSCLC Following Progression with EGFR TKI ( ULUAVOSI); **Revised Programs:** Expanded Eligibility Criteria for Palbociclib with Aromatase Inhibitor in Advanced Breast Cancer (UBRAVPALAI)
- **Drug Update – Drug Shortages Resolved:** Docetaxel, Vinorelbine
- **Benefit Drug List – New:** ULUAVOSI; **Deleted:** GUBCV, GUEMCYT, GUKIFN, PUM
- **Cancer Drug Manual – New:** Venetoclax; **Revised:** Bendamustine, Osimertinib
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts – New:** ULUAVOSI; **Revised:** BRAJDCARBT, BRAJZOL2, BRAJZOL5, UBRAVPALAI, BRAVTEST, BRAVTRVIN, CNBEV, UGILAN, UGOVOLAPM, GUBEP, ULYMIBRU, MOIT, UMYCARDEX, UMYCARLD, UMYLDF, UMYLDREL, UMYLENMTN, MYPAM, UMYPOMDEX, MYZOL, SAAJGI, SCPAINLI; **Deleted:** GUBCV, GUEMCYT, GUKIFN, PUM
- **Website Resources and Contact Information**

## EDITOR'S CHOICE

### NEW PROGRAMS

Effective 01 October 2018, the BC Cancer Provincial Systemic Therapy Program has approved the following treatment program:

#### Lung:

**Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Advanced Non-Small Cell Lung Cancer (ULUAVOSI)** – The BC Cancer Lung Tumour Group has implemented this new treatment program for patients who acquired the T790M mutation following progression on prior EGFR tyrosine kinase inhibitor (TKI) therapy (e.g. afatinib, gefitinib, erlotinib), and for those with *de novo* T790M mutation-positive disease. In a phase III randomized controlled trial (AURA 3), osimertinib demonstrated superior progression-free survival (PFS) compared to platinum-doublet chemotherapy (median PFS 10.1 mo vs. 4.4 mo, HR 0.30 95% CI 0.23-0.41) and improved tolerability.<sup>1</sup> The most commonly reported adverse events associated with osimertinib were diarrhea (41%), rash (34%), dry skin (23%) and paronychia (22%).

#### References:

1. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M positive lung cancer. N Engl J Med 2017;376:629-640.

## REVISED PROGRAMS

Effective 01 October 2018, the BC Cancer Provincial Systemic Therapy Program has revised the following treatment program:

### **Breast:**

**Expanded Eligibility Criteria for Palbociclib and Aromatase Inhibitor in Advanced Breast Cancer (UBRAVPALAI)** – The eligibility of this treatment program has been revised to include women with chemically-induced menopause using LHRH agonists and men. Patients must have ER-positive, HER2-negative disease, and have not received prior systemic treatment in the metastatic setting. To reflect this change, the protocol title has been updated to – “Therapy for Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor With or Without LHRH Agonist”.

## DRUG UPDATE

### DRUG SHORTAGES RESOLVED

#### **Docetaxel:**

The Canada-wide shortage of docetaxel from Pfizer Canada has now been resolved. All previous restrictions placed on docetaxel use at the BC Cancer can now be lifted.

#### **Vinorelbine:**

The prolonged and intermittent shortage of vinorelbine has been resolved as Teva Canada has now secured its vinorelbine inventory. All previous restrictions placed on vinorelbine use at the BC Cancer can now be lifted.

## BENEFIT DRUG LIST

### NEW PROGRAMS

Effective 01 October 2018, the following treatment programs have been added to the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer using Osimertinib	ULUAVOSI	Restricted

## DELETED PROGRAMS

Effective 01 October 2018, the following treatment programs have been deleted from the BC Cancer [Benefit Drug List](#):

Protocol Title	Protocol Code
Therapy for Transitional Cell Cancers using Carboplatin-Vinblastine	GUBCV
Androgen-Independent Prostate Cancer using Estramustine Phosphate (Interim Version)	GUEMCYT
Alpha-Interferon (α-IFN) for Advanced Renal Cell Carcinoma	GUKIFN
Monotherapy for Metastatic Carcinomas of Unknown Primary using Mitomycin (Standard)	PUM

## CANCER DRUG MANUAL

### NEW MONOGRAPHS AND PATIENT HANDOUTS

The following drugs are NOT BC Cancer Benefit Drugs, and require application to the BC Cancer Compassionate Access Program. Their corresponding Interim Monographs are made available for reference only. All BC Cancer drug monographs and patient handouts can be accessed [online](#) on the BC Cancer Drug Index.

The **Venetoclax Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Alina Gerrie (medical oncologist) and Linda Hamata (pharmacist) of the BC Cancer Lymphoma and Myeloma Tumour Group. Venetoclax is an oral small-molecule inhibitor which selectively binds to and inhibits the anti-apoptotic protein B-cell chronic lymphoma 2 (BCL-2), restoring apoptosis in BCL-2 dependent cancer cells. Venetoclax is indicated in the treatment of chronic lymphocytic leukemia. Initial dosing starts at 20 mg PO daily for 7 days, and slowly increased to 400 mg PO daily over 5 weeks by following a prescriptive ramp-up dosing schedule.

Highlights of these documents include:

- Tumour lysis syndrome, including fatalities, has occurred with treatment; hyperuricemia prophylaxis is recommended
- Myelosuppression is common with reported incidence of infection at 65%

### REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patient Handouts are listed below:

#### **Bendamustine Monograph** and **Chemotherapy Preparation and Stability Chart:**

- *Supply and Storage:* updated supplier to Teva; added information about storage in the refrigerator
- *Dosing:* updated adult dosing and BC Cancer protocols
- *Chemotherapy Preparation and Stability Chart:* revised recommended storage temperature; added 250 mL as a suggested bag size to maintain recommended concentration range when compounding smaller doses; added D2.5-1/2NS as an acceptable infusion solution

## CANCER DRUG MANUAL

### Osimertinib Monograph:

- *Dosing*: added new BC Cancer standard dosing and associated protocol

## CANCER DRUG MANUAL EDITORIAL BOARD CHANGES

The Cancer Drug Manual (CDM) Editorial Board would like to bid farewell to **Terri Gray** (RN, BC Cancer – Prince George) as she steps down from the Board to pursue other opportunities. The Board would like to thank Terri for her contributions to the CDM. The Board would also like to welcome two new nursing representatives – **Megan Crosby** (Clinical Nurse Educator, BC Cancer – Prince George) and **Michelle Lafreniere** (Clinical Nurse Educator, BC Cancer – Victoria).

## LIST OF REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

**BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts** are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter “U”.

### NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
ULUAVOSI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Treatment of EGFR T790M Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) with Osimertinib

### REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJDCARBT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Docetaxel diluent clarified</i>	Adjuvant Therapy for Breast Cancer using Docetaxel, Carboplatin, and Trastuzumab (HERCEPTIN®)
BRAJZOL2	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Adjuvant Treatment of Postmenopausal Women using 3-Monthly Zoledronic Acid
BRAJZOL5	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Adjuvant Treatment of Postmenopausal Women using 6-Monthly Zoledronic Acid
UBRAVPALAI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified; Title, Treatment, and Test sections revised</i>	Therapy of Advanced Breast Cancer using Palbociclib and Aromatase Inhibitor With or Without LHRH Agonist
BRAVTEST	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dosing clarified</i>	Palliative Therapy for Metastatic Breast Cancer using Testosterone Enanthate

REVISED PROTOCOLS, PPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAVTRVIN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and Vinorelbine
CNBEV	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Treatment section clarified</i>	Palliative Therapy for Recurrent Malignant Gliomas using Bevacizumab With or Without Concurrent Etoposide or Lomustine
UGILAN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dosing clarified</i>	Management of Functional Carcinoid and Neuroendocrine Tumors of the GI Tract using Lanreotide (SOMATULINE AUTOGEL®)
UGOOVOLAPM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Maintenance Treatment of Relapsed, BRCA-mutated, Platinum-Sensitive and Responsive Epithelial Ovarian Cancer using Olaparib
GUBEP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Drug administration sequence clarified</i>	Curative Therapy for Germ Cell Cancer using Bleomycin, Etoposide, Cisplatin
ULYMIBRU	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Treatment of Relapsed/Refractory Mantle-Cell Lymphoma using Ibrutinib
MOIT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility revised</i>	Therapy for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine
UMYCARDEX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Therapy of Multiple Myeloma using Carfilzomib and Dexamethasone With or Without Cyclophosphamide
UMYCARLD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone
UMYLDF	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Lenalidomide with Low-Dose Dexamethasone
UMYLDREL	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Therapy of Relapsed Multiple Myeloma using Lenalidomide with Dexamethasone
UMYLENMTN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests and Precautions clarified</i>	Maintenance Therapy of Multiple Myeloma using Lenalidomide
MYPAM	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Treatment of Multiple Myeloma with Pamidronate
UMYPOMDEX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests and Renal dosing clarified</i>	Therapy of Multiple Myeloma using Pomalidomide with Dexamethasone
MYZOL	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility and Treatment clarified</i>	Treatment of Multiple Myeloma with Zoledronic Acid

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
SAAJGI	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	Adjuvant Treatment of C-Kit Positive High-Risk Gastrointestinal Stromal Cell Tumours using Imatinib
SCPAINLI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Contact physician, Tests, Dosing and Institutional name updated</i>	Extreme Pain Therapy using Parenteral Lidocaine

DELETED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)				
CODE	Protocol	PPPO	Patient Handout	Protocol Title
GUBCV	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Therapy for Transitional Cell Cancers using Carboplatin-Vinblastine
GUEMCYT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Androgen-Independent Prostate Cancer using Estramustine Phosphate (Interim Version)
GUKIFN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Alpha-Interferon (a-IFN) for Advanced Renal Cell Carcinoma
PUM	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Monotherapy for Metastatic Carcinomas of Unknown Primary using Mitomycin (Standard)

## WEBSITE RESOURCES AND CONTACT INFORMATION

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604-877-6000 x 673028		<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Provincial Systemic Therapy Program	604-877-6000 x 672247		<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
To update contact information of any CON sites, please contact:			<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275		<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Nurse Educators	604-877-6000 x 672638		<a href="mailto:nursinged@bccancer.bc.ca">nursinged@bccancer.bc.ca</a>
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247		<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Provincial Professional Practice Nursing			<a href="mailto:BCCancerPPNAdmin@ehcnet.phsa.ca">BCCancerPPNAdmin@ehcnet.phsa.ca</a>
OSCAR	888-355-0355	604-708-2051	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a>
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820		<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
BC Cancer-Abbotsford	604-851-4710 Toll Free 877-547-3777		
BC Cancer-Prince George (Centre for the North)	250-645-7300 Toll Free 888-775-7300		
BC Cancer-Surrey	604-930-2098 Toll Free 800-523-2885		
BC Cancer-Kelowna	250-712-3900 Toll Free 888-563-7773		
BC Cancer-Vancouver	604-877-6000 Toll Free 800-663-3333		
BC Cancer-Victoria	250-519-5500 Toll Free 800-670-3322		

## EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)  
 Mario de Lemos, PharmD, MSc (Oncol)  
 Mark Goodwin, MLIS

Jagbir Kaur, RN, MN  
 Caroline Lohrisch, MD  
 Alison Pow, BSc(Pharm)